Eric Singhi/faculty.mdanderson.org
Jul 1, 2025, 08:59
Eric Singhi on Progress in SCLC with ABBV-706 Early-Phase Data
Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared a post on X by DAVA Oncology, adding:
“Exciting to see how the field is moving forward for our patients with SCLC!”
Quoting DAVA Oncology‘s post:
“Dr. Millie Das presented early-phase data on ABBV-706, a novel SEZ6-targeted ADC delivering a topo I payload.
In relapsed/refractory SCLC, ORR reached 60.9%. Safety manageable; biomarker role still unclear.
Combo trials with PD-1/platinum ongoing. “
More posts featuring Eric Singhi on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 20, 2025, 11:17
Jul 20, 2025, 10:28
Jul 20, 2025, 10:28
Jul 20, 2025, 10:17
Jul 20, 2025, 10:08
Jul 20, 2025, 09:16